Statement on the 2012 Guideline for the treatment of psoriatic arthritis with biologics

Dr E MacPhie - on behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SAGWG)

The 2012 guideline is now due for revision. After discussion with members of the Working Group (Neil McHugh and Laura Coates) it has been decided that a review of the guideline should be postponed until 2017. This decision has been made in light of the publication in 2015 of NICE TA340 (ustekinumab for treating active psoriatic arthritis) and the awaited NICE TA regarding secukinumab which is due to be published in 2017.

In addition to providing recommendations about treatment options the 2012 guideline also provided guidance on safety issues and anti-TNF therapy. Relevant guidance on anti-TNF therapy will be included in upcoming revisions of

- the 2010 BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies,
- the 2010 BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
- and the 2013 BSR and BHPR guidelines for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.

These guidelines are being combined and expanded to cover all biologics prescribed for all types of inflammatory arthritis (i.e. rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis) that have NICE approval.

The relevant guideline working groups have also been asked to also include ustekinumab and to cover safety issues specific to other types of inflammatory arthritis including psoriatic arthritis. This guideline is expected to be published in 2017.

Proposed Date for Revision: 2017